Can Drug Delivery Go Green and Go Home?

Portal, Kindeva, and Credence reshape biologic care with smarter, greener delivery

27 Oct 2025

The delivery of biologic drugs in America is being quietly remade. A new generation of companies is rethinking how complex medicines reach patients and where they are taken. From connected injectors to eco-friendly inhalers, these firms are turning once-clinical procedures into everyday acts.

Portal Instruments leads the charge. Its PRIME NEXUS injector, developed with Regeneron, lets patients self-administer biologics that once required hospital supervision. The system translates clinical data into consumer-grade design, a shift one analyst describes as “bringing the medicine to the patient, not the other way around.” By combining digital monitoring with needle-free delivery, Portal hopes to make home treatment both easier and safer.

Kindeva Drug Delivery is tackling a different problem: the environmental cost of inhalers. In partnership with Orbia, it is developing propellants with lower global-warming potential, aligning with new European rules to phase down harmful gases. The approach allows drugmakers to meet climate targets without compromising performance, a timely advantage as regulators tighten oversight.

Credence MedSystems, meanwhile, has signed a manufacturing agreement with SMC Pharma Services to scale up its dual-chamber syringe. The device can mix and deliver complex therapies in one step, reducing dosing errors and supporting the rise of personalized medicine.

Together these efforts point to a more decentralised model of care, one that prizes convenience, safety and sustainability as much as efficacy. Many of the technologies remain in early testing or limited rollout, yet the momentum is evident.

Regulatory hurdles and production challenges still loom, but the direction of travel is clear. Biologic delivery is becoming more personal, portable and patient-driven. America’s innovators are not just improving treatment, they are redefining what it means to receive it.